The purpose of this paper is to present a detailed investigation of the advantages of employing GraphLIME (Local Interpretable Model Explanations for Graph Neural Networks) for the trustworthy prediction of diabetes mellitus. Our pursuit involves identifying the strengths of GraphLIME combined with the attention-mechanism over the standard coupling of deep learning neural networks with the original LIME method. The system build this way, provided us a proficient method for extracting the most relevant features and applying the attention mechanism exclusively to those features. We have closely monitored the performance metrics of the two approaches and conducted a comparative analysis. Leveraging attention mechanisms, we have achieved an accuracy of 92.6% for the addressed problem. The model’s performance is meticulously demonstrated throughout the study, and the results are furthermore evaluated using the Receiver Operating Characteristic (ROC) curve. By implementing this technique on a dataset of 768 patients diagnosed with or without diabetes mellitus, we have successfully boosted the model’s performance by over 18%.

The authors have declared no competing interest.

This study did not receive any funding

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.

Yes